Jie Wu, PhD


wie-j

The University of Oklahoma Health Sciences Center
Stanton L. Young Biomedical Research Center
975 NE 10th St, Rm BRC 411B
Oklahoma City, OK 73104

Phone: 405-271-8001, x 31092
E-Mail: jie-wu@ouhsc.edu

Titles

Professor of Pathology
Peggy and Charles Stephenson Endowed Chair in Cancer Translational Research
Co-leader, Cell Signaling and Oncogenes Team, Stephenson Cancer Center
Oklahoma TSET Research Scholar

Education

Xiamen University
Xiamen, China
B.S., 1982

Shanghai Institute of Cell Biology
Chinese Academy of Sciences
Shanghai, China
Graduate Student, 1983

University of Kansas Medical Center
Kansas City, KS
Ph.D., 1988

Memorial Sloan-Kettering Cancer Center
New York, NY
Postdoc, 1990

University of Virginia
Charlottesville, VA
Postdoc, 1994

Research Interests/Sub-Specialty

  • Protein kinases and phosphatases

  • Tumor biology

  • Animal models

  • Cancer genomics

  • Drug discovery and development

  • Sensitivity and resistance to therapy

  • Precision medicine

Publications

  1. Dorsey JF, Cunnick JM, Mane SM, and Wu J.  Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of the Bcr-Abl+ K562 cells by Gab2. Blood. 2002 Feb 15: 99(4): 1388-1397.
  2. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla K, and Wu J.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005 Sep; 4(9): 1311-1319.
  3. Ren Y, Chen Z, Chen L, Woods NT, Reuther GW, Cheng JQ, Wang HG, and Wu J.  Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2007 Dec 14; 282(50): 36463-36473.
  4. Chen L, Pernazza D, Scott L, Lawrence HR, Ren Y, Luo Y, Wu X, Sung S, Guida WC, Sebti SM, Lawrence NJ, and Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem Pharmacol. 2010 Sep 15;80(6): 801-810.
  5. Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, Koomen J, and Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer. 2010 Oct; 1(10): 994-1007.
  6. Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, and Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013 Oct 24;3, 3042; doi:10.1038/srep03042.
  7. Schneeberger V, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, and Wu J. (2014) SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014 Aug;35(8):1717-25. doi: 10.1093/carcin/bgu025. Epub 2014 Jan 30.
  8. Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, and Wu J.  Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. 2015 Mar20;6(8): 6191-6202.
  9. Fan C, Chen L, Huang Q, Tao S, Welsh EA, Teer JK, Cai J, Cress WD, and Wu J.  Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer. 2015 Dec 22;113(12): 1735-1743.
  10. Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, and Wu J. (2016) Preclinical modeling of KIF5B-RET fusion lung cancer. Mol Cancer Ther. 15, 2521-2529.